U.S. markets open in 9 minutes
  • S&P Futures

    3,770.75
    +26.50 (+0.71%)
     
  • Dow Futures

    30,407.00
    +218.00 (+0.72%)
     
  • Nasdaq Futures

    13,158.75
    +53.25 (+0.41%)
     
  • Russell 2000 Futures

    2,128.40
    +24.10 (+1.15%)
     
  • Crude Oil

    53.39
    +0.54 (+1.02%)
     
  • Gold

    1,862.50
    +13.60 (+0.74%)
     
  • Silver

    26.33
    +0.95 (+3.73%)
     
  • EUR/USD

    1.2130
    +0.0019 (+0.16%)
     
  • 10-Yr Bond

    1.0430
    +0.0290 (+2.86%)
     
  • Vix

    30.21
    +7.19 (+31.23%)
     
  • GBP/USD

    1.3689
    -0.0002 (-0.02%)
     
  • USD/JPY

    104.3950
    +0.3230 (+0.31%)
     
  • BTC-USD

    32,032.95
    +1,328.89 (+4.33%)
     
  • CMC Crypto 200

    650.02
    +22.36 (+3.56%)
     
  • FTSE 100

    6,523.14
    -44.23 (-0.67%)
     
  • Nikkei 225

    28,197.42
    -437.79 (-1.53%)
     

SHAREHOLDER ALERT: Halper Sadeh LLP is Investigating the Following Companies; Investors are Encouraged to Contact the Firm - MYOK, EIDX, CBMG

·2 min read

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:

(PRNewsfoto/Halper Sadeh LLP)
(PRNewsfoto/Halper Sadeh LLP)

MyoKardia, Inc. (NASDAQ: MYOK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bristol-Myers Squibb Company for $225.50 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/myokardia-inc-myok-stock-merger-bristol-myers/.

Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc. Under the merger agreement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos common stock owned. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/eidos-therapeutics-inc-eidx-stock-merger-bridgebio/.

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/cellular-biomedicine-group-inc-cbmg-stock-merger/.

Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-halper-sadeh-llp-is-investigating-the-following-companies-investors-are-encouraged-to-contact-the-firm--myok-eidx-cbmg-301156147.html

SOURCE Halper Sadeh LLP